Microbiota, Mucus, and Modulators: Cystic Fibrosis Infection Pathogenesis in the Cystic Fibrosis Transmembrane...

Area of Science:

• Pulmonary Medicine
• Microbiology
• Genetics

Background:

• Cystic fibrosis (CF) lung disease stems from defective CFTR-mediated ion transport, leading to dehydrated mucus and chronic airway infections.
• CF airways harbor polymicrobial ecosystems, including Pseudomonas aeruginosa and Staphylococcus aureus, driving inflammation and bronchiectasis.
• CFTR modulators enhance airway hydration and reduce pathogen load, but established infections often persist.

Purpose of the Study:

• To review the impact of CFTR modulators on chronic CF airway infections.
• To identify knowledge gaps in understanding infection dynamics during CFTR modulator therapy.
• To discuss implications for infection management in the CFTR modulator era.

Main Methods:

• Literature review focusing on CF airway infections and CFTR modulator therapy.
• Analysis of current understanding of pathogenesis, microbiome interactions, and sampling techniques.
• Synthesis of information regarding clinical outcomes and management strategies.

Main Results:

• CFTR modulators improve airway hydration and reduce pathogen acquisition but do not eliminate established chronic infections.
• Long-term effects of CFTR modulators on infection dynamics and disease progression require further investigation.
• Existing gaps in knowledge include infection pathogenesis, airway-gut microbiome interplay, and optimal sampling methods.

Conclusions:

• Despite advances with CFTR modulators, chronic infection remains a significant challenge in cystic fibrosis care.
• Further research is needed to understand and manage complex airway infections in individuals receiving CFTR modulator therapy.
• Addressing knowledge gaps in pathogenesis, microbiome, sampling, and management is crucial for optimizing patient outcomes.